Telemedicine Improves Accessibility of CAR T-Cell Therapy
Sarah Murawski, MPAS, discusses how telemedicine can impact the use of chimeric antigen receptor T-cell therapy in patients with cancer at the Association of Community Cancer Centers National Oncology Conference.
Sarah Murawski, MPAS, physician assistant in Medicine at the Vanderbilt University Medical Center, discusses how telemedicine can impact the use of chimeric antigen receptor (CAR) T-cell therapy in patients with cancer at the Association of Community Cancer Centers (ACCC) National Oncology Conference.
CAR T-cell therapy is still new. Murawski says we don’t know a lot about these agents, but telemedicine will be essential and provide more patients with access to this treatment. Currently, CAR T-cell therapy is not offered at every institution.
